News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trevena, Inc. Initiates Clinical Development of TRV130, a Biased Mu-Opioid Ligand for Severe Post-Operative Pain


2/13/2012 6:40:22 AM

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today the initiation of a Phase I clinical trial of TRV130, a novel candidate designed for the intravenous treatment of moderate-to-severe post-operative pain. TRV130 is a biased ligand that targets the mu-opioid receptor to optimize analgesia while minimizing mu opioid receptor-mediated side effects such as respiratory suppression and constipation. As a biased ligand, TRV130 activates the G-protein signaling pathway mediated by the mu-opioid receptor while antagonizing the ß-arrestin pathway. In preclinical studies, TRV130 was powerfully analgesic with an improved safety and tolerability profile when compared directly to classical opioids such as morphine.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES